These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32021340)

  • 1. Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis.
    Johnson C; Stephens J; Walker C; Cappelleri JC; Shelbaya A
    Clinicoecon Outcomes Res; 2020; 12():57-67. PubMed ID: 32021340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis.
    Shelbaya A; Solem CT; Walker C; Wan Y; Johnson C; Cappelleri JC
    Clinicoecon Outcomes Res; 2018; 10():213-222. PubMed ID: 29670383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
    Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
    Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA.
    Estes SJ; Soliman AM; Zivkovic M; Chopra D; Zhu X
    Adv Ther; 2020 Jun; 37(6):2777-2791. PubMed ID: 32399813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls.
    Bedenbaugh AV; Bonafede M; Marchlewicz EH; Lee V; Tambiah J
    Clinicoecon Outcomes Res; 2021; 13():421-435. PubMed ID: 34054301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic impact of switching from metoprolol to nebivolol for hypertension treatment: a retrospective database analysis.
    Chen S; Tourkodimitris S; Lukic T
    J Med Econ; 2014 Oct; 17(10):685-90. PubMed ID: 25007315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses.
    Mehta D; Davis M; Epstein AJ; Wensel B; Grinnell T; Williams GR
    Neurol Ther; 2020 Dec; 9(2):585-598. PubMed ID: 32949379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
    Karasawa Y; Kamae I; Nozawa K; Zeniya S; Murata T; Soen S; Sakamoto C
    PLoS One; 2021; 16(7):e0253547. PubMed ID: 34228745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.
    Tada Y; Kim H; Spanopoulos D; Habiro K; Tsuritani K; Yamada Y; Mandal A; Zhong Y; Hikichi Y
    J Dermatol; 2022 Nov; 49(11):1106-1117. PubMed ID: 35946343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
    Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
    J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
    Collantes-Estevez E; Fernandez-Perez C
    Curr Med Res Opin; 2003; 19(5):402-10. PubMed ID: 13678477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.